Kathryn Romano is CAO at Krystal Biotech, Inc. (KRYS). They have made 2 open-market trades across 1 company since 2023, most recently 2026-03-02.
CIK 0001801385
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KRYS | 23,116 | $7.3M |
Shares reported on the most recent Form 4, priced at the 2026-03-03 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KRYS | SELL | 2026-03-02 | 2026-03-03 | $267.60 | $201K | -7.4% | -2.3% | +11.7% |
| KRYS | SELL | 2026-02-09 | 2026-02-11 | $272.14 | $3.4M | -3.1% | -10.3% | +12.5% |
| KRYS | SELL · 10b5-1 | 2025-02-27 | 2025-02-28 | $175.22 | $131K | -0.4% | +0.7% | -29.9% |
| KRYS | SELL · 10b5-1 | 2024-02-28 | 2024-03-01 | $165.70 | $1.8M | +5.3% | +3.4% | -5.1% |
| KRYS | SELL · 10b5-1 | 2024-02-28 | 2024-03-01 | $165.92 | $1.4M | +5.3% | +3.4% | -5.1% |
| KRYS | SELL · 10b5-1 | 2024-02-26 | 2024-02-28 | $136.91 | $1.1M | +3.2% | +6.7% | -3.7% |
| KRYS | SELL · 10b5-1 | 2024-01-22 | 2024-01-24 | $130.00 | $325K | -13.7% | -14.1% | +25.1% |
| KRYS | SELL · 10b5-1 | 2023-05-19 | 2023-05-23 | $102.34 | $7.0M | +5.9% | +4.3% | +9.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.